Cargando…

2529. Population pharmacokinetic models for cefepime and enmetazobactam derived from pooled Phase 1 to Phase 3 clinical studies

BACKGROUND: The investigational β-lactam/β-lactamase inhibitor combination of cefepime (FEP)/enmetazobactam (ENM) met criteria for non-inferiority and superiority compared to piperacillin/tazobactam in a phase 3 clinical trial of adult patients with complicated urinary tract infections (cUTI)/acute...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vollmer, Jannik, Belley, Adam, Velicitat, Patrick, Machacek, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677492/ http://dx.doi.org/10.1093/ofid/ofad500.2147

Ejemplares similares

637. Treatment Outcomes in Secondary Analysis Populations of Adult Patients the ALLIUM Phase 3 study Comparing Cefepime-Enmetazobactam to Piperacillin-Tazobactam for Complicated Urinary Tract Infections (cUTI) or Acute Pyelonephritis (AP)
por: Kaye, Keith S, et al.
Publicado: (2021)

LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales
por: Belley, Adam, et al.
Publicado: (2020)

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021
por: Belley, Adam, et al.
Publicado: (2023)

1477. A Randomized Phase 2 Study of Cefepime Combined with the Novel Extended Spectrum β-Lactamase Inhibitor Enmetazobactam in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP)
por: Carmeli, Yehuda, et al.
Publicado: (2019)

1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients
por: Liu, Jiajun, et al.
Publicado: (2019)

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015
por: Morrissey, Ian, et al.
Publicado: (2019)

2529. Child HIV Exposure and CMV Seroprevalence in Botswana: No Associations with 24-Month Growth and Neurodevelopment
por: Moraka, Natasha Onalenna, et al.
Publicado: (2019)

2564. Population Pharmacokinetics and Pharmacodynamics of Cefepime in Hospitalized Obese and Non-Obese Patients
por: Shin, Beomjin, et al.
Publicado: (2023)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

A Statistical Report on 2529 Cases of Cancer of the Breast
por: Harnett, W. L.
Publicado: (1948)

Studies on enmetazobactam clarify mechanisms of widely used β-lactamase inhibitors
por: Lang, Pauline A., et al.
Publicado: (2022)

2529: Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Caribbean Hispanics
por: Suarez, Dagmar Fredy Hernandez, et al.
Publicado: (2018)

1535. Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of Cefepime (CPM) in Obese and Non-Obese Patients
por: Morrisette, Taylor, et al.
Publicado: (2019)

1394. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime
por: Liu, Jiajun, et al.
Publicado: (2018)

1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
por: Kois, Abigail K, et al.
Publicado: (2021)

Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants
por: Zhao, Yang, et al.
Publicado: (2020)

A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations
por: Talha Zahid, Muhammad, et al.
Publicado: (2023)

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
por: McGovern, Paul C, et al.
Publicado: (2022)

2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI)
por: Dorr, Mary Beth, et al.
Publicado: (2023)

1286. Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC)
por: Mack, Andrew R, et al.
Publicado: (2021)

Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease
por: Caruso, Antonello, et al.
Publicado: (2020)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
por: Groff, Lindsey, et al.
Publicado: (2018)

2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)
por: Purdy, Andrew Scott, et al.
Publicado: (2023)

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
por: Cammarata, Anthony P, et al.
Publicado: (2023)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

726. Risk factor analysis for cefepime and piperacillin/tazobactam resistant organisms
por: Pham, Tho H, et al.
Publicado: (2023)

2528. Cefepime Induced Neurotoxicity in Patients With or Without a History of Seizures
por: Baalbaki, Nadeem, et al.
Publicado: (2023)

Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro
por: Schwameis, Richard, et al.
Publicado: (2008)

Influence of endotoxin induced fever on the pharmacokinetics of intramuscularly administered cefepime in rabbits
por: Goudah, Ayman, et al.
Publicado: (2006)

544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial
por: Kumar, Princy N, et al.
Publicado: (2018)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies
por: Trang, Michael, et al.
Publicado: (2019)

1380. Effect of Absolute Body Weight on Clinical Outcomes of Obese Patients Treated with Cefepime
por: Wagner, Jamie L, et al.
Publicado: (2018)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

628. Utilizing Cefepime Therapeutic Drug Monitoring for Patients at Risk of or Exhibiting Signs of Neurotoxicity
por: Au, Joanna, et al.
Publicado: (2022)

2178. Resistance to Cefepime/Taniborbactam in NDM-1 -Are We Losing the Battle against MDROs?
por: Ono, Daisuke, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
por: Álvarez, José C., et al.
Publicado: (2021)

2789. Cefepime Versus Non-Cefepime/Non-Carbapenem Therapy for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Subgroup Analysis of The Carbapenem-Serratia Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tqvoe7s9j4sdcj4ke7gvobonid